Clinical Application of the Expression of LOXL2 mRNA and Tenascin-C mRNA in Tissues of the Bile Duct Cancer
10.3969/j.issn.1671-7414.2017.03.021
- VernacularTitle:胆管癌组织LOXL2mRNA与Tenascinm-C mRNA表达的临床应用研究
- Author:
Xiaoping XIAO
;
Ling GUO
;
Xiong ZHANG
- Keywords:
bile duct cancer;
LOXL2 mRNA;
Tenascin-C mRNA
- From:
Journal of Modern Laboratory Medicine
2017;32(3):79-81
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the clinical application of the expression of LOXL2 mRNA and Tenascin-C mRNA in tissues for the disease with the bile duct cancer.Methods The serum and clinical data in 35 cases of patients with the bile duct cancer (cancer group) and 28 cases of patients with normal bile duct tissue (control group) were collected,used the real-time fluorescent quantitative PCR (real-time-PCR,RT-PCR) technology to detect the expression of LOXL2 mRNA and TenascinC mRNA in tissues toobserve the relationship between the changes and the bile duct cancer for the two markers.Results The expression of LOXL2 mRNA and Tenascin-C mRNA in tissues in the cancer group were 1.27±0.18 and 1.39±0.19,which of ones in the control group were 0.20±0.06 and 0.23±0.06.In the cancer group,the expression of LOXL2 mRNA and Tenascin-C mRNA in tissues respectively with comparision to those in the control group were significantly higher,the differences had statistical significance(t=52.18,56.87,P＜0.01),which of ones in the cancer group was positively related (r=0.687,P＜0.01).Conclution The expression of LOXL2 mRNA and Tenascin-C mRNA in tissues may be a molecular targets for the disease with the bile duct cancer in the early diagnosis and judgment of progression in the courses of this disease.
